- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07695389
Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects. (BIOMOHS)
A Multicenter, Prospective, Randomized Controlled Clinical Trial Assessing the Efficacy of a Novel Cellular, Acellular, Matrix-like Product (CAMP) Plus Standard of Care Versus Standard of Care Alone in the Management of Post-Mohs Micrographic Surgery Defects.
A multicenter, prospective, randomized controlled clinical trial assessing the efficacy of a novel cellular, acellular, matrix-like product (CAMP) plus standard of care versus standard of care alone in the management of post-mohs micrographic surgery defects.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
This study will utilize a Prospective, Multicenter, Randomized Controlled Clinical Trial design.
Subjects will be adult patients undergoing Mohs micrographic surgery with resulting post-excisional defects suitable for healing by secondary intention or management with a topical matrix-like product.
Subjects will be randomized to receive:
- CAMP plus Standard of Care (SOC), or
- Control Dressing plus SOC. Randomization will occur after confirmation of final Mohs stage and measurement of the post-excisional defect.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Bennett Sarver
- Telefonnummer: 1-833-865-6300
- E-Mail: info@serenagroups.com
Studienorte
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74132
- Rekrutierung
- Southside Dermatology Mohs and Skin Surgery
-
Kontakt:
- Ana Montalva
- Telefonnummer: (918) 760-0700
- E-Mail: amontalva@dermatologyok.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
The potential subject must be at least 18 years of age or older.
-
The potential subject must have undergone Mohs micrographic surgery for a cutaneous malignancy (e.g., basal cell carcinoma, or squamous cell carcinoma).
-
The potential subject must have a post-Mohs surgical defect that is suitable for treatment with a CAMP product or healing by secondary intention.
-
The surgical site has received standard Mohs excision and hemostasis with no requirement for immediate flap or graft reconstruction as determined by the treating surgeon.
-
If the surgical defect is on the lower extremity, the limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:
- Ankle-Brachial Index (ABI) between 0.7 and ≤ 1.3;
- Toe-Brachial Index (TBI) ≥ 0.6;
- Transcutaneous Oxygen Measurement (TCOM) ≥ 40 mmHg;
- Pulse Volume Recording (PVR): biphasic.
-
If the subject has multiple Mohs defects, they must be separated by at least 2 cm. The largest defect satisfying the inclusion and exclusion criteria will be designated as the target wound.
-
The potential subject must agree to attend the weekly study visits required by the protocol.
-
The potential subject must be willing and able to participate in the informed consent process.
Exclusion Criteria:
-
The potential subject is known to have a life expectancy of < 6 months.
-
The potential subject's target wound is not secondary to a Mohs excision.
-
The target wound is infected or there is cellulitis in the surrounding skin.
-
The target wound:
- Exposes tendon, bone, or joint space, and/or
- Requires immediate complex flap or graft reconstruction in the judgment of the surgeon.
-
The potential subject has participated in a clinical trial involving treatment with an investigational product within the previous 30 days.
-
The potential subject has glycated hemoglobin (HbA1c) greater than 10% within 3 months of the initial screening visit.
-
The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Control Dressing + Standard of Care
Standard of care will be cleaning, debridement, ulcer moisture balance, control dressing and offloading. |
Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
|
Sonstiges: CAMP + Standard of Care
Membrane Wrap-Lite is a human amniotic membrane tissue allograft derived from human placental tissue. |
Participants will receive weekly applications of Membrane Wrap-Lite and Standard of Care until ulcer closure, or a maximum of 6 weeks, whichever occurs first. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Complete Wound Closure
Zeitfenster: 1-6 Weeks
|
The percentage of target wounds achieving complete wound closure in 6 weeks. |
1-6 Weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Time to Closure
Zeitfenster: 1-6 Weeks
|
Time to closure for the target wound. |
1-6 Weeks
|
|
Percentage Area Reduction
Zeitfenster: 1-6 weeks
|
Percentage wound area reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 weeks
|
|
Procedure-Related Adverse Events
Zeitfenster: 1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Wound Volume Reduction
Zeitfenster: 1-6 Weeks
|
Percentage wound volume reduction from TV-1 to TV-6 measured weekly with digital photographic planimetry using imaging device and physical examination. |
1-6 Weeks
|
|
Product or Procedure Adverse Events
Zeitfenster: 1-6 Weeks
|
The number of product- or procedure-related adverse events. |
1-6 Weeks
|
|
Numeric Pain Scale
Zeitfenster: 1-6 weeks
|
Change in pain at the target wound site assessed using a numeric pain scale. 0 being no pain and 10 being the worst pain imaginable. |
1-6 weeks
|
|
Economic Outcomes
Zeitfenster: 1-6 Weeks
|
Health economic outcomes, including direct and indirect cost of care. |
1-6 Weeks
|
|
Quality of Life
Zeitfenster: 1- 6 Weeks
|
Change in quality of life, using the Wound Quality of Life Questionnaire, with items scored 0-4, where higher scores indicate worse quality of life. |
1- 6 Weeks
|
|
Scare and Cosmetic Outcomes
Zeitfenster: 12 Months
|
Scar and cosmetic outcomes at 12 months using the Patient and Observer Scar Assessment Scale (POSAS). 0 being normal and 10 being very different. |
12 Months
|
|
Time to Complete Granulation Tissue
Zeitfenster: 1-6 Weeks
|
Time to complete granulation tissue confirmed by independent assessment. |
1-6 Weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Perfusion
Zeitfenster: 1-6 Weeks
|
Changes in local perfusion at the surgical site over the 6-week treatment period, assessed via near-infrared spectroscopy. |
1-6 Weeks
|
|
Rate of Recurrence
Zeitfenster: 12 Months
|
The rate of recurrence within 12 months of closure when applicable. |
12 Months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Thomas Serena, MD, Serena Group, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- To be determined
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .